Protagonist Therapeutics, INC Form 4 insider transactions

Protagonist Therapeutics CEO, Dinesh V. Patel, sold a significant number of shares and exercised stock options, according to a recent SEC filing.

Protagonist Therapeutics CEO, Dinesh V. Patel, gifted 1,000 shares of common stock to his grandchild.

Protagonist Therapeutics' Chief Medical Officer, Arturo Molina, sold 1,906 shares of common stock to cover tax obligations related to the settlement of restricted stock units.

Asif Ali, CFO of Protagonist Therapeutics, reports the sale of common stock and the exercise of stock options.

Director William D. Waddill of Protagonist Therapeutics reports the acquisition and disposal of common stock and stock options on September 10, 2024.

Director William D. Waddill of Protagonist Therapeutics, Inc. reports the acquisition and disposal of common stock and stock options on July 24, 2024.

Dinesh V. Patel, CEO of Protagonist Therapeutics, gifted 1,000 shares of common stock to his grandchild on June 13, 2024.

Director William D. Waddill exercised stock options and sold shares of Protagonist Therapeutics, Inc. on June 7, 2024, according to a Form 4 filing.

Dinesh V. Patel, CEO of Protagonist Therapeutics, sold 35,000 shares of common stock at an average price of $35.19 per share on June 7, 2024, under a pre-arranged Rule 10b5-1 trading plan.

Asif Ali, CFO of Protagonist Therapeutics, sold 1,234 shares of common stock on April 18, 2024, to cover tax withholding obligations.

Protagonist Therapeutics' CEO, Dinesh V. Patel, Ph.D., sold 25,000 shares of common stock on April 1, 2024, under a pre-arranged Rule 10b5-1 trading plan.

Harold E. Selick, a director at Protagonist Therapeutics, exercised stock options to acquire 6,490 shares of common stock at $1.89 per share on March 7, 2024.

Protagonist Therapeutics' CEO, Dinesh V. Patel, Ph.D., sold 30,000 shares of common stock on March 1, 2024, under a pre-arranged Rule 10b5-1 trading plan.

Director William D. Waddill exercised stock options and sold shares of Protagonist Therapeutics, Inc. on March 1, 2024, according to a Form 4 filing with the SEC.

Asif Ali, CFO of Protagonist Therapeutics, reports the sale of common stock and the exercise of stock options in recent transactions.

Dinesh V. Patel, CEO of Protagonist Therapeutics, sold shares to cover tax obligations related to vesting restricted stock units.

Suneel Gupta, Chief Development Officer of Protagonist Therapeutics, reports the withholding of shares to cover tax obligations upon vesting of restricted stock units.